332 research outputs found
Masterplan Transitie Visserijvloot : memorandum haalbaarheidsonderzoek
Memorandum over de transitie van de visserijvloo
Masterplan Transitie Visserijvloot : memorandum haalbaarheidsonderzoek
Memorandum over de transitie van de visserijvloo
Specificity of the Organic Acid Activation of Alternative Oxidase in Plant Mitochondria
Bioavailability and toxicity after oral administration of m-iodobenzylguanidine (MIBG)
meta-iodobenzylguanidine (MIBG) radiolabelled with iodine-131 is used for diagnosis and treatment of neuroadrenergic neoplasms such as phaeochromocytoma and neuroblastoma. In addition, non-radiolabelled MIBG, administered i.v., is used in several clinical studies. These include palliation of the carcinoid syndrome, in which MIBG proved to be effective in 60% of the patients. Oral MIBG administration might be convenient to maintain palliation and possibly improve the percentage of responders. We have, therefore, investigated the feasibility of oral administration of MIBG in an animal model. Orally administered MIBG demonstrated a bioavailability of 59%, with a maximal tolerated dose of 60 mg kg−1. The first and only toxicity encountered was a decrease in renal function, measured by a reduced clearance of [51Cr]EDTA and accompanied by histological tubular damage. Repeated MIBG administration of 40 mg kg−1for 5 sequential days or of 20 mg kg−1for two courses of 5 sequential days with a 2-day interval did not affect renal clearance and was not accompanied by histological abnormalities in kidney, stomach, intestines, liver, heart, lungs, thymus, salivary glands and testes. Because of a sufficient bioavailability in absence of gastrointestinal toxicity, MIBG is considered suitable for further clinical investigation of repeated oral administration in patients. 1999 Cancer Research Campaig
The growing importance of continuing medical education in nuclear medicine: The role of the European School of Nuclear Medicine
In summary, the ESNM provides educational activities not only for young colleagues but also for established nuclear medicine physicians. There is also close contact with physicists, radiopharmacists and technologists. In the future, more interactive education and increasing activities on the web are planned. On behalf of all members of the School, I (P.L.) would like to thank Andrea Bauer and her team at the executive secretariat in Vienna for their professional help in organising the meetings and hosting the ESNM
The Induction of IgM and IgG Antibodies against HLA or MICA after Lung Transplantation
The production of IgG HLA antibodies after lung transplantation (LTx) is considered to be a major risk factor for the development of chronic rejection, represented by the bronchiolitis obliterans syndrome (BOS). It has recently been observed that elevated levels of IgM HLA antibodies also correlates with the development of chronic rejection in heart and kidney transplantation. This study investigates the relationship between IgM and IgG antibodies against HLA and MICA after lung transplantation. Serum was collected from 49 patients once prior to transplantation and monthly for up to 1 year after lung transplantation was analyzed by Luminex to detect IgM and IgG antibodies against HLA and MICA. The presence of either IgM or IgG HLA and/or MICA antibodies prior to or after transplantation was not related to survival, gender, primary disease, or the development of BOS. Additionally, the production of IgG alloantibodies was not preceded by an increase in levels of IgM, and IgM levels were not followed by an increase in IgG. Under current immune suppressive regimen, although the presence of IgM antibodies does not correlate with BOS after LTx, IgM
high IgG
low HLA class I antibody titers were observed more in patients with BOS compared to patients without BOS
Overcoming scientific barriers in the transition from in vivo to non-animal batch testing of human and veterinary vaccines
INTRODUCTION : Before release, vaccine batches are assessed for quality to evaluate whether they meet
the product specifications. Vaccine batch tests, in particular of inactivated and toxoid vaccines, still
largely rely on in vivo methods. Improved vaccine production processes, ethical concerns, and suboptimal
performance of some in vivo tests have led to the development of in vitro alternatives.
AREAS COVERED : This review describes the scientific constraints that need to be overcome for replacement
of in vivo batch tests, as well as potential solutions. Topics include the critical quality attributes of
vaccines that require testing, the use of cell-based assays to mimic aspects of in vivo vaccine-induced
immune responses, how difficulties with testing adjuvanted vaccines in vitro can be overcome, the use
of altered batches to validate new in vitro test methods, and how cooperation between different
stakeholders is key to moving the transition forward.
EXPERT OPINION : For safety testing, many in vitro alternatives are already available or at an advanced
level of development. For potency testing, in vitro alternatives largely comprise immunochemical
methods that assess several, but not all critical vaccine properties. One-to-one replacement by
in vitro alternatives is not always possible and a combination of methods may be required.The Dutch Ministry of Agriculture, Nature and Food Quality, the National Institute of Public Health & the Environment and Intravacc.https://www.tandfonline.com/loi/ierv20am2022Veterinary Tropical Disease
Biopsy confirmation of metastatic sites in breast cancer patients:clinical impact and future perspectives
Determination of hormone receptor (estrogen receptor and progesterone receptor) and human epidermal growth factor receptor 2 status in the primary tumor is clinically relevant to define breast cancer subtypes, clinical outcome,and the choice of therapy. Retrospective and prospective studies suggest that there is substantial discordance in receptor status between primary and recurrent breast cancer. Despite this evidence and current recommendations,the acquisition of tissue from metastatic deposits is not routine practice. As a consequence, therapeutic decisions for treatment in the metastatic setting are based on the features of the primary tumor. Reasons for this attitude include the invasiveness of the procedure and the unreliable outcome of biopsy, in particular for biopsies of lesions at complex visceral sites. Improvements in interventional radiology techniques mean that most metastatic sites are now accessible by minimally invasive methods, including surgery. In our opinion, since biopsies are diagnostic and changes in biological features between the primary and secondary tumors can occur, the routine biopsy of metastatic disease needs to be performed. In this review, we discuss the rationale for biopsy of suspected breast cancer metastases, review issues and caveats surrounding discordance of biomarker status between primary and metastatic tumors, and provide insights for deciding when to perform biopsy of suspected metastases and which one (s) to biopsy. We also speculate on the future translational implications for biopsy of suspected metastatic lesions in the context of clinical trials and the establishment of bio-banks of biopsy material taken from metastatic sites. We believe that such bio-banks will be important for exploring mechanisms of metastasis. In the future,advances in targeted therapy will depend on the availability of metastatic tissue
- …